Observational studyChest2021
Ratio of FEV
Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- New spirometry recommendations from the Brazilian Thoracic Association - 2024 update.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Guideline
- Penicillin Allergy Labels, Broad-Spectrum Antibiotic Use, and Chronic Obstructive Pulmonary Disease Exacerbations: A Population-Based Cohort Study from China.Infection and drug resistance · 2026Article
- Post-lung transplant surveillance in 2026: current practice, variability, and the need for standardization.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
- Phenotypes and Trajectories of Tobacco-exposed Persons with Preserved Spirometry: Insights from Lung Volumes.Annals of the American Thoracic Society · 2025Article
- Comparison between patients with COPD and healthy subjects on spatiotemporal, moment and kinematic parameters: A quasi-experimental study.Health science reports · 2024Article
- The Role of Pulmonary Function Testing in the Diagnosis and Management of COPD.Respiratory care · 2023Review
- Prevalence of abnormal spirometry in individuals with a smoking history and no known obstructive lung disease.Respiratory medicine · 2023Article
- Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.American journal of respiratory and critical care medicine · 2022Observational
- The prevalence and physiological impacts of centrilobular and paraseptal emphysema on computed tomography in smokers with preserved ratio impaired spirometry.ERJ open research · 2022Article
Corrections and comments
- Commented on by
Authors and funding
32 authors at 15 institutions in 1 country.
Spyridon FortisCenter for Access & Delivery Research & Evaluation (CADRE), Iowa City VA Health Care System, Iowa City, IA. Electronic address: spyridon-fortis@uiowa.edu.
Alejandro P ComellasDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Occupation Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA.
Surya P BhattDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL.
Eric A HoffmanDepartments of Radiology, Biomedical Engineering and Medicine, University of Iowa, Iowa City, IA.
MeiLan K HanDepartment of Medicine, University of Michigan, Ann Arbor, MI.
Nirav R BhaktaDepartment of Medicine, University of California, San Francisco, CA.
Robert PaineDepartment of Pulmonary Medicine, University of Utah, Salt Lake City, UT.
Bonnie RonishDepartment of Pulmonary Medicine, University of Utah, Salt Lake City, UT.
Richard E KannerDepartment of Pulmonary Medicine, University of Utah, Salt Lake City, UT.
Mark DransfieldDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL; Division of Pulmonary and Critical Care Medicine, Birmingham VA Medical Center, Birmingham, AL.
Daniel HoestereyDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA.
Russell G BuhrDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA; Department of Medicine, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA.
R Graham BarrDepartment of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY.
Brett DolezalDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA.
Victor E OrtegaDepartment of Internal Medicine, Section on Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC.
M Bradley DrummondDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.
Mehrdad ArjomandiDepartment of Medicine, University of California, San Francisco, CA; San Francisco Veterans Affairs Healthcare System, San Francisco, CA.
Robert J KanerDepartments of Medicine and Genetic Medicine, Weill Cornell Medicine, New York, NY.
Victor KimDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Jeffrey L CurtisDepartment of Medicine, University of Michigan, Ann Arbor, MI; Medicine Service, VA Ann Arbor Healthcare System, Ann Arbor, MI.
Russell P BowlerDepartment of Medicine, National Jewish Medical and Research Center, Denver, CO.
Fernando MartinezDepartments of Medicine and Genetic Medicine, Weill Cornell Medicine, New York, NY.
Wassim W LabakiDepartment of Medicine, University of Michigan, Ann Arbor, MI.
Christopher B CooperDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA; Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA; Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Wanda K O'NealDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.
Gerald CrinerDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Nadia N HanselDepartment of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA.
Jerry A KrishnanDivision of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, IL.
Prescott WoodruffDepartment of Medicine, University of California, San Francisco, CA.
David CouperDepartment of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC.
Donald TashkinDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA.
Igor BarjaktarevicDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA.
University of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Michigan–Ann Arbor · USUniversity of North Carolina at Chapel Hill · USUniversity of Utah · USTemple University · USUniversity of Alabama at Birmingham · USUniversity of Iowa · USColumbia University · USCornell University · USIowa City VA Health Care System · USNational Jewish Health · USUniversity of Illinois Chicago · USWake Forest University · USWeill Cornell Medicine · US
Funding
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5MSPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9MThe Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1MNRSA Training CoreTL1TR001883 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI, Nina Thawata Harawa · 2016 to 2026
$8.6MTRAINING IN RESPIRATORY AND ENVIRONMENTAL MEDICINET32HL007106 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES, DOERSCHUK, CLAIRE M · 1985 to 2021
$7.3MSPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2MParametric Response Mapping in COPDR01HL122438 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HAN, MEILAN K, MARTINEZ, FERNANDO J · 2014 to 2017
$4.0MCathelicidin and Vitamin D: Impact on Populations At-Risk and with COPDR01HL125432 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DRUMMOND, MICHAEL BRADLEY · 2015 to 2019
$3.1MStructural Determinants of Disease Progression in COPDR01HL151421 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATT, SURYA P., NAKHMANI, ARIE · 2020 to 2024
$2.6MDefining Pathways in COPD Patient Oriented ResearchK24HL138188 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MeiLan K Han · 2017 to 2026
$1.2MMentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2MDiastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseK23HL133438 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATT, SURYA P. · 2016 to 2020
$921kCSRD VA I01 CX000911NCATS NIH HHS KL2 TR001882NCATS NIH HHS TL1 TR001883NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K23 HL133438NHLBI NIH HHS K24 HL137013NHLBI NIH HHS K24 HL138188NHLBI NIH HHS R01 HL122438NHLBI NIH HHS R01 HL125432NHLBI NIH HHS R01 HL151421NHLBI NIH HHS T32 HL007106NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762NIBIB NIH HHS R21 EB027891NIEHS NIH HHS P30 ES005605
Abstract
backgroundMild expiratory flow limitation may not be recognized using traditional spirometric criteria based on the ratio of FEV RESEARCH QUESTION: Does slow vital capacity (SVC) instead of FVC increase the sensitivity of spirometry to identify patients with early or mild obstructive lung disease? STUDY DESIGN AND
methodsWe included 854 current and former smokers from the Subpopulations and Intermediate Outcome Measures in COPD Study cohort with a postbronchodilator FEV
resultsParticipants with FEV
interpretationLow FEV TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01969344T4; URL: www.clinicaltrials.gov.
Indexed as
SmokersDisease ProgressionFollow-Up StudiesForced Expiratory VolumeHumansLungProspective StudiesPulmonary Disease, Chronic ObstructiveSpirometryTomography, X-Ray ComputedVital CapacityCOPDpulmonarypulmonary function testslow vital capacitySVC
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.